Lisata Therapeutics M&A Deal with Marea Therapeutics, Inc.
Lisata Therapeutics filed an amendment to its previous 8-K to provide required audited financial statements and pro forma financial information following its completed acquisition of Marea Therapeutics, Inc. The filing includes combined financial statements for Marea and M2 Therapeutics for the years 2024 and 2025, as well as interim 2026 data.
- Counterparty
- Marea Therapeutics, Inc.